Drugs / Paclitaxel
Paclitaxel
Drug Approved in the United StatesTaxane mitotic inhibitor·First approved·1993
- Registered trials
- 2163
- Ongoing
- 501/ 23%
- Completed
- 1140
- Indications
- 4
Approved indications
| Indication |
|---|
| Breast cancer |
| Ovarian cancer |
| Non-small cell lung cancer |
| Kaposi's sarcoma |
Clinical trial landscape
2163 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 967 | 217 | 516 | |
| Phase 3 | 477 | 147 | 226 | |
| Phase 1 | 367 | 50 | 238 | |
| Phase 1/2 | 213 | 48 | 104 | |
| Phase 2/3 | 47 | 18 | 13 | |
| Not applicable | 34 | 8 | 15 | |
| Unknown | 32 | 4 | 18 | |
| Phase 4 | 15 | 3 | 8 | |
| Early Phase 1 | 11 | 6 | 2 | |
| All phases | 2163 | 501 | 1140 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Stabilizes microtubule polymer and protects it from disassembly, disrupting mitotic spindle function and triggering apoptosis.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.